Inside oncology’s research boom

The long list of new treatments reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics. New drugs for lung, breast, skin and blood cancers have made gains over standard of care, while other additions have expanded options for patients.


With spotlight on FDA, Congress weighs reforms to accelerated drug approvals

FDA panel supports agency push to raise approval bar for certain cancer drugs

CAR-T treatment moves earlier as FDA widens approval of Gilead’s Yescarta



Share the Post:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to our use of all cookies, however, you may visit “Cookies Setting” to provide a controlled consent.

Privacy Policy